Skip to main content
. 2011 Jun;55(6):2961–2967. doi: 10.1128/AAC.01377-10

Table 3.

Population pharmacokinetic parameters of tenofovir from the final model for 36 HIV-infected pregnant women after receiving 600 mg of TDF at the onset of labor and for their 36 neonates enrolled in the TEmAA ANRS 12109 Trial, Step 2a

Structural model parameter Estimate by structural model (% RSE) Statistical model
Parameter Estimate (% RSE)
ka 0.651 h−1 (13) ωCL/F 39% (22)
CL/F 189 liters/h (11) ωV1/F 165% (13)
V1/F 482 liters (34) ωQ/F 63% (19)
Q/F 230 liters/h (16)
V2/F 3,500 liters (23) ωkan 177% (15)
k1F 0.259 h−1 (38) ωCLn/F 68% (9)
kF1 0.691 h−1 (31) ωVn/F 46% (18)
kFC 0.157 h−1 (49) σmother plasma 0.03 mg · liter−1 (4)
km 0.0495 h−1 (29) σcord plasma 0.014 mg · liter−1 (12)
kem 0.005 h−1 (fixed) σneonate plasma 47% (12)
kan 0.518 h−1 (38) σcord TFV cells 63.2 fmol/106 cells (16)
CLn/F 3.01 liters/h (13) σneonate TFV cells 105% (16)
Vn/F 37.7 liters (17) σcord TFV-DP cells 33.4 fmol/106 cells (16)
Vn/F, θGA 8.5 (32) σneonate TFV-DP cells 114% (16)
a

RSE, relative standard error (standard error of estimate/estimate · 100); ka, absorption rate constant; CL/F, maternal apparent elimination clearance from the central compartment; V1/F, apparent volume of distribution of the central maternal compartment; Q/F, apparent maternal intercompartmental clearance; V2/F, apparent volume of distribution of the peripheral maternal compartment; k1F, maternal-to-fetal rate constant; kF1, fetal-to-maternal rate constant; kFC, fetal-to-cord rate constant; kan, neonatal absorption; CLn/F, neonatal apparent elimination clearance; Vn/F, apparent neonatal volume of distribution; Vn/F, θGA, influential factor for gestational age on neonatal apparent volume of distribution; km, TFV-to-intracellular TFV-DP metabolism constant rate; kem, TFV-DP elimination constant rate; σ, residual variability estimates (CV of residual variability [%]); and ω, interindividual variability estimates (CV of intersubject variability [%]).